| Literature DB >> 30459193 |
Matthew J Dorman1, Theresa Feltwell1, David A Goulding1, Julian Parkhill1, Francesca L Short2,3.
Abstract
Klebsiella pneumoniae infections affect infants and the immunocompromised, and the recent emergence of hypervirulent and multidrug-resistant K. pneumoniae lineages is a critical health care concern. Hypervirulence in K. pneumoniae is mediated by several factors, including the overproduction of extracellular capsule. However, the full details of how K. pneumoniae capsule biosynthesis is achieved or regulated are not known. We have developed a robust and sensitive procedure to identify genes influencing capsule production, density-TraDISort, which combines density gradient centrifugation with transposon insertion sequencing. We have used this method to explore capsule regulation in two clinically relevant Klebsiella strains, K. pneumoniae NTUH-K2044 (capsule type K1) and K. pneumoniae ATCC 43816 (capsule type K2). We identified multiple genes required for full capsule production in K. pneumoniae, as well as putative suppressors of capsule in NTUH-K2044, and have validated the results of our screen with targeted knockout mutants. Further investigation of several of the K. pneumoniae capsule regulators identified-ArgR, MprA/KvrB, SlyA/KvrA, and the Sap ABC transporter-revealed effects on capsule amount and architecture, serum resistance, and virulence. We show that capsule production in K. pneumoniae is at the center of a complex regulatory network involving multiple global regulators and environmental cues and that the majority of capsule regulatory genes are located in the core genome. Overall, our findings expand our understanding of how capsule is regulated in this medically important pathogen and provide a technology that can be easily implemented to study capsule regulation in other bacterial species.IMPORTANCE Capsule production is essential for K. pneumoniae to cause infections, but its regulation and mechanism of synthesis are not fully understood in this organism. We have developed and applied a new method for genome-wide identification of capsule regulators. Using this method, many genes that positively or negatively affect capsule production in K. pneumoniae were identified, and we use these data to propose an integrated model for capsule regulation in this species. Several of the genes and biological processes identified have not previously been linked to capsule synthesis. We also show that the methods presented here can be applied to other species of capsulated bacteria, providing the opportunity to explore and compare capsule regulatory networks in other bacterial strains and species.Entities:
Keywords: Klebsiellazzm321990; TraDIS; capsular polysaccharide; capsule regulation; pathogenesis
Mesh:
Substances:
Year: 2018 PMID: 30459193 PMCID: PMC6247091 DOI: 10.1128/mBio.01863-18
Source DB: PubMed Journal: mBio Impact factor: 7.867
FIG 1Summary of density-dependent TraDISort strategy. (A) Electron microscope image of capsulated K. pneumoniae NTUH-K2044. (B) Schematic of the density-TraDISort strategy to identify capsule regulators. A high-density transposon library is applied to the top of a discontinuous Percoll gradient, which is then centrifuged at moderate speed to separate capsulated and noncapsulated mutants. The separate fractions are sequenced to identify transposon-gDNA junctions. (C) Validation of the Percoll gradient method for separating cells by capsule phenotype. Individual fractions immediately following separation on a Percoll gradient were adjusted to an OD600 of 4 in sterile PBS and were assayed for uronic acid content. Statistical significance was evaluated by one-way analysis of variance (ANOVA) followed by Tukey’s honestly significant difference (HSD) test, and data are reported for each fraction relative to the input sample (**, P < 0.01; ***, P < 0.001).
FIG 2(A) Results of TraDIS mapping at the capsule locus of K. pneumoniae NTUH-K2044. Transposon insertions in capsule genes were very abundant in the input sample. The majority of these mutants were not found in the top fraction but were instead enriched in the middle fraction (e.g., gnd and galF) or the bottom fraction (all genes from wcaJ to wzi). Genes defined as hits in our screen are shown in yellow and others in gray. (B) Insertion mutations in genes of the sap ABC transporter locus were not found in the middle fraction, suggesting higher capsule production than wild type. Genes which are putative increased capsule hits are shown in blue, with others in gray. Note that sapD had a very low number of reads in all fractions. The flanking genes, codB and KP1_2336, are examples of genes where transposon insertion does not change capsule, and such insertion mutants were found in both the top and middle fractions. (C) Common and strain-specific genes required for full capsule production in K. pneumoniae NTUH-K2044 and ATCC 43816. Putative increased-capsule mutants are not considered in this chart. These two strains share approximately 4,200 genes, and the majority of genes required for full capsule production are present in both strains. Sixteen genes were defined as capsule related in both strains. Note that the gene content of the cps locus differs between these two strains, which accounts for the majority of hits in strain-specific genes.
Genes in which mutants have altered capsule production
| Gene | Annotation | Proportion | Locus tag | |
|---|---|---|---|---|
| NTUH-K2044 | ATCC 43816 | |||
| Low-capsule mutants | ||||
| | WzxE protein | 0.94 | ||
| | ECA polymerase | 1.00 | ||
| | Transcriptional activator RfaH | 1.00 | ||
| | Replication initiation regulator SeqA | 0.99 | ||
| | Phosphoglucomutase | 1.00 | ||
| | 6-Phosphogluconate dehydrogenase | 0.69 | ||
| | Colanic acid biosynthsis UDP-glucose lipid carrier transferase WcaJ | 0.20 | ||
| | Polysaccharide export protein | 0.98 | ||
| | Outer membrane protein | 0.99 | ||
| | PAP2 family protein | 0.93 | ||
| | ABC transporter | 1.00 | ||
| | 4-Amino-4-deoxy- | 1.00 | ||
| | SMR family multidrug resistance protein | 0.95 | ||
| | Polymyxin resistance protein PmrJ | 1.00 | ||
| | Glutathione reductase | 1.00 | ||
| | Deacetylase | 1.00 | ||
| | Undecaprenyl-phosphate N-acetylglucosaminyl 1-phosphate transferase | 0.98 | ||
| | Translation elongation factor P Lys34:lysine transferase | 1.00 | ||
| | tRNA delta(2)-isopentenylpyrophosphate transferase | 1.00 | ||
| | RNA polymerase-binding transcription factor | 0.99 | ||
| | Chaperone protein HtpG | 0.97 | ||
| | Mannose-6-phosphate isomerase | 0.65 | ||
| | Arginine/ornithine antiporter ArcD | 1.00 | ||
| | Electron transport complex protein RnfA | 0.98 | ||
| | Electron transport complex protein RnfC | 0.38 | ||
| | Electron transport complex protein RnfD | 0.99 | ||
| | Electron transport complex protein RnfE | 0.78 | ||
| | Transcriptional regulator SlyA | 1.00 | ||
| | Major outer membrane lipoprotein | 1.00 | ||
| | UTP-glucose-1-phosphate uridylyltransferase | 0.97 | ||
| | BarA-associated response regulator UvrY (GacA, SirA) | 1.00 | ||
| | Regulator of mucoid phenotype | 0.05 | ||
| | Mannose-1-phosphate guanylyltransferase | 0.24 | ||
| | UDP-glucose pyrophosphorylase | 0.88 | ||
| | DNA-binding capsular synthesis response regulator RcsB | 0.77 | ||
| | Nitrogen regulatory protein P-II | 1.00 | ||
| | 23S rRNA pseudouridine synthase D | 0.96 | ||
| | Transcription repressor | 1.00 | ||
| | BarA sensory histidine kinase | 0.92 | ||
| | Transcription elongation factor GreA | 0.99 | ||
| | Aerobic respiration control sensor protein arcB | 1.00 | ||
| | Arginine pathway regulatory protein ArgR | 1.00 | ||
| | Osmolarity sensory histidine kinase EnvZ | 0.90 | ||
| | Osmolarity response regulator | 1.00 | ||
| | Lipopolysaccharide core biosynthesis protein RfaZ | 0.76 | ||
| | O-Antigen polymerase | 0.78 | ||
| | Lipopolysaccharide heptosyltransferase III | 1.00 | ||
| | Glycosyltransferase | 1.00 | ||
| | EF-P beta-lysylation protein EpmB | NA | NA | |
| | Putative glycosyl transferase | 0.11 | NA | |
| | GDP-mannose mannosyl hydrolase | 0.05 | NA | |
| | GDP-fucose synthetase | 0.11 | NA | |
| | GDP-mannose 4,6-dehydratase | 0.13 | NA | |
| | Galactoside O-acetyltransferase | 0.00 | NA | |
| | Glycosyltransferase | 0.06 | NA | |
| | Mucoviscosity-associated protein | 0.06 | NA | |
| | Polysaccharide pyruvyl transferase | 0.05 | NA | |
| | Repeat unit exporter | 0.06 | NA | |
| | Tyrosine-protein kinase Wzc | 0.06 | NA | |
| | Putative protein tyrosine phosphatase | 0.00 | NA | |
| | Carbon storage regulatory sRNA | NA | NA | |
| | Regulator of mucoid phenotype | NA | NA | |
| | Glucose-6-phosphate isomerase | 1.00 | ||
| | Flavodoxin | 0.99 | ||
| | Aerobic glycerol-3-phosphate dehydrogenase | 0.99 | ||
| | Putative ABC transporter ATP-binding protein YrbF | 1.00 | ||
| | ABC transporter | 1.00 | ||
| | ABC transporter | 1.00 | ||
| | lipoprotein | 1.00 | ||
| | Putative acid phosphatase Wzb | 0.01 | NA | |
| | Tyrosine autokinase | 0.08 | NA | |
| | Group 1 glycosyl transferase | 0.08 | NA | |
| | Group 1 glycosyl transferase | 0.08 | NA | |
| | Group 1 glycosyl transferase | 0.08 | NA | |
| | Lipid A core–O-antigen ligase and related enzymes | 0.08 | NA | |
| | Colanic acid exporter | 0.08 | NA | |
| | Hypothetical protein | 0.08 | NA | |
| | Putative lipopolysaccharide biosynthesis O-acetyl transferase WbbJ | 0.06 | NA | |
| High-capsule mutants | ||||
| | DNA polymerase I | 0.79 | ||
| | Adenylate cyclase | 0.99 | ||
| | Potassium transport protein | 1.00 | ||
| | Adenylosuccinate synthetase | 1.00 | ||
| | Diadenosinetetraphosphatase | 0.96 | ||
| | Pyruvate dehydrogenase E1 component | 0.98 | ||
| | PII uridylyl-transferase | 0.94 | ||
| | Hemolysin expression modulating protein | 0.99 | ||
| | Putative inner membrane protein involved in the | 1.00 | ||
| | Translocation protein TolB precursor | 1.00 | ||
| | Periplasmic glucans biosynthesis protein | 1.00 | ||
| | Glucosyltransferase | 0.93 | ||
| | ABC-type peptide transport system ATP-binding component | 0.97 | ||
| | ABC-type peptide transport system permease component | 1.00 | ||
| | ABC-type peptide transport system permease component | 0.99 | ||
| | ABC-type peptide transport system periplasmic component | 0.68 | ||
| | Pyruvate kinase | 0.99 | ||
| | DNA-binding protein HLP-II/pleiotropic regulator | 0.99 | ||
| | Carboxy-terminal protease for penicillin-binding protein 3 | 0.11 | ||
| | Acetate/propionate kinase | 1.00 | ||
| | Phosphate acetyltransferase | 0.80 | ||
| | SsrA tmRNA-binding protein | 1.00 | ||
| | Sugar-specific PTS family enzyme IIA component | 1.00 | ||
| KP1 | 0.95 | |||
| | DNA-binding protein | 1.00 | ||
| | Putative low-affinity inorganic phosphate transporter | 0.84 | ||
A list of all statistically significant genes from this TraDIS screen which, when disrupted by transposon insertion, increase capsule production in K. pneumoniae. Cutoff criteria are described in Materials and Methods. Gene names and functional annotations are taken from the pan-genome consensus file (see Materials and Methods). The complete data set, including statistical data, is provided in Table S3 and S4.
Note that the pan-genome includes only protein-coding sequences located on the chromosome, so the small RNA csrB gene and plasmid-encoded rmpA2 gene are not included in our pan-genome analysis.
Locus tags are shown in bold for hits and in italics where the gene was not called as a hit.
FIG 3Validation of putative capsule regulators with single-gene-deletion mutants. (A) Percoll gradient centrifugation of clean deletion mutants in selected NTUH-K2044 genes. All of the genes tested showed reduced density compared to the wild type (WT), with the exception of the putative increased-capsule mutant, ΔsapBDEF, which stayed above the 15% Percoll layer. (B) Validation of ATCC 43816 deletion mutant phenotypes on 35% to 50% Percoll gradients. The ΔarnF and ΔrfaH mutants showed reduced density compared to the wild type, while the ΔmprA mutant did not, in contrast to its phenotype in NTUH-K2044. (C) Hypermucoidy tests with K. pneumoniae NTUH-2044 mutants. Strains were grown to late stationary phase and cultures centrifuged for 5 min at 1,000 × g. The OD600 of the supernatant was measured and is presented here as a proportion of the starting OD600. *, P < 0.05; ***, P < 0.001 (one-way ANOVA followed by Tukey’s HSD test, relative to the wild type).
FIG 4Complementation and electron microscopy of K. pneumoniae NTUH-K2044 ΔargR, ΔmprA, ΔslyA, and ΔsapBCDF mutants. (A) Hypermucoidy assay. Strains were centrifuged at 1,000 × g for 5 min to define decreased hypermucoidy relative to the wild type or at 2,500 × g to identify increases in hypermucoidy relative to the wild type. Significant differences are indicated as follows: **, P < 0.01; ***, P < 0.001 (one-way ANOVA and Tukey’s HSD test). The data represent results from an experiment conducted independently of the experiment whose results are represented in Fig. 3C. comp, complemented. (B) Uronic acid assay to confirm the capsule phenotype of each strain. Differences relative to the wild type were evaluated by pairwise one-way ANOVA with Benjamini-Hochberg correction for multiple testing. *, P < 0.05; **, P < 0.001; ***, P < 0.0001. (C) Transmission electron microscopy images of K. pneumoniae NTUH-K2044 and its ΔargR, ΔmprA, ΔslyA, and ΔsapBCDF mutants. Red arrows indicate the boundary of the gel-like layer of the sapBCDF mutant capsule.
FIG 5Virulence of selected mutants. (A) Killing of research-grade Galleria mellonella larvae by infection with K. pneumoniae NTUH-K2044 wild-type or mutant strains. Larvae were infected at an inoculum of 105. Differences in killing compared to the wild type were evaluated using the Kaplan-Meier log rank test and are indicated as follows: *, P < 0.05; **, P < 0.01; ***, P < 0.001. (B) Survival in human serum. Differences relative to the wild type are indicated as follows: **, P < 0.01; ***, P < 0.001 (pairwise one-way ANOVA). (C) Expression of several capsule-related genes in strain NTUH-K2044 ΔsapBCDF. Transcript abundance was measured using the relative standard curve method with recA as a reference gene, and data were normalized to the WT. *, P < 0.05; ***, P < 0.001 (one-way ANOVA).
FIG 6Overview of capsule regulation in NTUH-K2044. Products are colored red for mutants with low capsule and blue for mutants with high capsule, and those genes that were validated in clean deletion knockouts are indicated with bold labels and outlines. Likely modes of action are indicated by green or red arrows for predicted positive and negative effects on transcription of the capsule locus. Gray arrows indicate inputs that may affect capsule synthesis without modulating transcription. Omitted are individual capsule biosynthetic genes, ECA biosynthetic genes, and components of the transcription and translation machinery.